Insiders · CBIO

CBIO insider transactions

Crescent Biopharma Inc. (CBIO) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for CBIO

• 5d
  SEC Form 4 filed by Director Violin Jonathan

  4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
• 5d
  SEC Form 4 filed by Director Lubner David Charles

  4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
• 5d
  SEC Form 4 filed by Director Balcom Alexandra

  4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
• 5d
  SEC Form 4 filed by Director Moran Susan

  4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
• 5d
  SEC Form 4 filed by Director Fairmount Funds Management Llc

  4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
• 173d
  Chief Scientific Officer Pinkas Jan was granted 22,507 units of Ordinary Shares (SEC Form 4)

  4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
• 173d
  Chief Business Officer Doughty Christopher Grant was granted 22,714 units of Ordinary Shares, increasing direct ownership by 58% to 62,194 units (SEC Form 4)

  4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
• 173d
  Chief Executive Officer Brumm Joshua T was granted 55,117 units of Ordinary Shares, increasing direct ownership by 21% to 323,517 units (SEC Form 4)

  4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
• 173d
  Chief Financial Officer Scalzo Richard William was granted 19,422 units of Ordinary Shares (SEC Form 4)

  4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
• 173d
  President and COO Mcneill Jonathan was granted 25,507 units of Ordinary Shares, increasing direct ownership by 19% to 159,707 units (SEC Form 4)

  4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
• 173d
  Chief Medical Officer Im Ellie Eunkyung was granted 21,298 units of Ordinary Shares (SEC Form 4)

  4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
• 173d
  Officer Lynch Ryan was granted 12,378 units of Ordinary Shares (SEC Form 4)

  4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
• 173d
  Officer Bispham Barbara Harlin was granted 18,422 units of Ordinary Shares (SEC Form 4)

  4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
• 180d
  SEC Form 4 filed by President and COO Mcneill Jonathan

  4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
• 180d
  SEC Form 4 filed by Chief Executive Officer Brumm Joshua T

  4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
• 182d
  Director Fairmount Funds Management Llc bought $18,237,600 worth of Ordinary Shares (1,360,000 units at $13.41) (SEC Form 4)

  4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
• 327d
  SEC Form 4 filed by Chief Scientific Officer Pinkas Jan

  4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
• 328d
  SEC Form 3 filed by new insider Pinkas Jan

  3 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
• 929d
  Luo Ying acquired 2,840,376 shares (SEC Form 4)

  4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
• 929d
  SEC Form 4 filed by Ye Weiguo

  4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
• 929d
  SEC Form 4 filed by Ma Songjiang

  4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
• 929d
  SEC Form 4 filed by Chen Ruoyu

  4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
• 929d
  Gni Group Ltd. acquired 63,588,119 shares (SEC Form 4)

  4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
• 929d
  SEC Form 4 filed by Wu Charles C

  4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
• 929d
  New insider Ma Songjiang claimed ownership of 2,942,467 shares (SEC Form 3) (Amendment)

  3/A - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
• 951d
  SEC Form 4 filed by Luo Ying

  4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
• 951d
  SEC Form 4 filed by Eastling Thomas Wilson

  4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
• 951d
  SEC Form 4 filed by Usman Nassim

  4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
• 951d
  SEC Form 4 filed by Ying Han

  4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
• 951d
  SEC Form 4 filed by Parry Renate

  4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
• 951d
  SEC Form 4 filed by Chen Ruoyu

  4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
• 951d
  SEC Form 4 filed by Carmichael Gordon

  4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
• 951d
  SEC Form 3 filed by new insider Carmichael Gordon

  3 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
• 951d
  SEC Form 3 filed by new insider Ma Songjiang

  3 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
• 951d
  SEC Form 3 filed by new insider Ye Weiguo

  3 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
• 951d
  SEC Form 3 filed by new insider Parry Renate

  3 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
• 951d
  SEC Form 3 filed by new insider Chen Ruoyu

  3 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
• 951d
  SEC Form 3 filed by new insider Ying Han

  3 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
• 951d
  SEC Form 3 filed by new insider Wu Charles C

  3 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
• 955d
  Gni Hong Kong Ltd disposed of 5,371,304 shares, closing all direct ownership in the company (SEC Form 4)

  4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
• 955d
  New insider Gni Group Ltd. claimed ownership of 6,266,521 shares (SEC Form 3)

  3 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
• 1011d
  SEC Form 4: Miller Seline E. returned 6 units of Series Y Preferred Stock to the company, closing all direct ownership in the company

  4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
• 1011d
  SEC Form 4: Lawlor Augustine returned 49 units of Series Y Preferred Stock to the company, closing all direct ownership in the company

  4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
• 1011d
  SEC Form 4: Usman Nassim returned 34 units of Series Y Preferred Stock to the company, closing all direct ownership in the company

  4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
• 1011d
  SEC Form 4: Gni Group Ltd. returned 6,267 units of Series Y Preferred Stock to the company

  4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
• 1011d
  SEC Form 4: Hunt Andrea returned 28 units of Series Y Preferred Stock to the company, closing all direct ownership in the company

  4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
• 1250d
  SEC Form 3: New insider Gni Group Ltd. claimed ownership of 6,266,521 shares

  3 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
• 1250d
  SEC Form 3 filed by new insider Eastling Thomas Wilson

  3 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
• 1250d
  SEC Form 3 filed by new insider Luo Ying

  3 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
• 1398d
  SEC Form 4: Usman Nassim bought $1,528 worth of shares (3,250 units at $0.47), increasing direct ownership by 15% to 24,541 units

  4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
• 1398d
  SEC Form 4: Miller Seline E. bought $1,528 worth of shares (3,250 units at $0.47), increasing direct ownership by 100% to 6,500 units

  4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
• 1398d
  SEC Form 4: Blouse Grant E. bought $1,528 worth of shares (3,250 units at $0.47), increasing direct ownership by 53% to 9,417 units

  4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
• 1566d
  SEC Form 4 filed by Miller Seline E.

  4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
• 1566d
  SEC Form 4 filed by Blouse Grant E.

  4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
• 1573d
  SEC Form 4: Usman Nassim bought $1,495 worth of shares (3,250 units at $0.46), increasing direct ownership by 18% to 21,291 units

  4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
• 1573d
  SEC Form 4: Miller Seline E. bought $1,495 worth of shares (3,250 units at $0.46)

  4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
• 1573d
  SEC Form 4: Blouse Grant E. bought $1,495 worth of shares (3,250 units at $0.46), increasing direct ownership by 111% to 6,167 units

  4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
• 1613d
  SEC Form 4: Williams Eddie was granted 12,308 shares, increasing direct ownership by 55% to 34,804 units

  4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
• 1613d
  SEC Form 4: Ling Geoffrey M.D. was granted 12,855 shares, increasing direct ownership by 68% to 31,790 units

  4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
• 1613d
  SEC Form 4: Hunt Andrea was granted 7,521 shares, increasing direct ownership by 36% to 28,228 units

  4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)